Teva Pharmaceutical Industries Limited (TEVA)
- Previous Close
13.18 - Open
13.17 - Bid --
- Ask --
- Day's Range
12.75 - 13.21 - 52 Week Range
7.09 - 14.47 - Volume
8,890,350 - Avg. Volume
10,492,993 - Market Cap (intraday)
14.475B - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
-- - EPS (TTM)
-0.50 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 27, 2017
- 1y Target Est
15.50
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
www.tevapharm.com35,001
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: TEVA
Related Videos: TEVA
Performance Overview: TEVA
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TEVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TEVA
Valuation Measures
Market Cap
15.00B
Enterprise Value
31.93B
Trailing P/E
--
Forward P/E
5.37
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.90
Price/Book (mrq)
1.93
Enterprise Value/Revenue
2.02
Enterprise Value/EBITDA
20.49
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.53%
Return on Assets (ttm)
4.54%
Return on Equity (ttm)
-7.36%
Revenue (ttm)
15.85B
Net Income Avi to Common (ttm)
-559M
Diluted EPS (ttm)
-0.50
Balance Sheet and Cash Flow
Total Cash (mrq)
3.23B
Total Debt/Equity (mrq)
249.48%
Levered Free Cash Flow (ttm)
3.29B
Research Analysis: TEVA
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: TEVA
Analyst Report: Teva Phar Inds Lt
Teva Pharmaceutical Industries Ltd. is the world's largest generic pharmaceutical manufacturer, with roughly 76 billion tablets and capsules produced annually. The company has roughly 37,000 employees and over 53 manufacturing facilities across more than 33 countries. One of every 12 prescriptions in the U.S. is filled with Teva products.
RatingNeutralPrice TargetMarket Update: TEVA
Stocks were mostly higher on Wednesday morning after a three-day losing streak ahead of Friday's PCE reading. Trump Media & Technology Group (DJT) is up 15%, while GameStop is down 15% after reporting disappointing 4Q results. The S&P 500 rose 0.2%, the Dow was up 0.6% and the Nasdaq lost 0.2%. Crude oil traded below $82 per barrel and gold was up $12 to $2211 per ounce.
Analyst Report: Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
RatingNeutralPrice TargetAnalyst Report: Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
RatingNeutralPrice Target